SCHEMBL16797607

SCHEMBL16797607

CCC1(CC)Oc2ccccc2C(CCOC(=O)C(C)(C)C)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.35
POLB P06746 1/20 0.33
PRKCA P17252 2/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
LMNA P02545 3/20 0.33
PKM P14618 2/20 0.33
CHRM2 P08172 2/20 0.33
CHRM1 P11229 2/20 0.33
KCNH2 Q12809 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
TRPV1 Q8NER1 1/20 0.32
GAA P10253 1/20 0.32
GBA1 P04062 1/20 0.32
MAPT P10636 1/20 0.32
RECQL P46063 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PRKCE Q02156 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16797697 0.82 LMNA (0.33) ABCB1POLBPRKCAKMT2AMEN1
SCHEMBL16809476 0.81 LMNA (0.33) ABCB1POLBPRKCAKMT2AMEN1
SCHEMBL18181881 0.77 KCNE1 (0.30) KCNE1KCNQ1
SCHEMBL18181941 0.77 KCNE1 (0.30) KCNE1KCNQ1
SCHEMBL18182093 0.77 KCNE1 (0.30) KCNE1KCNQ1
SCHEMBL16809561 0.77 SIGMAR1 (0.37) KMT2AMEN1LMNATRPV1KCNE1
SCHEMBL18177750 0.76 CA2 (0.40) LMNAKCNE1KCNQ1
SCHEMBL17130503 0.76 CA2 (0.40) LMNAKCNE1KCNQ1
SCHEMBL18169299 0.76 CA2 (0.40) LMNAKCNE1KCNQ1
SCHEMBL16797625 0.74 KCNE1 (0.39) KMT2AMEN1LMNAKCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10081615-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-09-25 US disclosed
EP-3079687-B1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS CO LTD (KR) 2018-02-28 EP disclosed
US-20160311792-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-20160311792-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-20160311792-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
EP-3079687-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2016-10-19 EP disclosed
WO-2015088272-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-10-01 WO disclosed
WO-2015088272-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311792-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain SULT2A1, SULT1A1, TRPV1 ABCB1 2655/4885POLB 4621/4885PRKCA 3590/4885
US-10081615-B2 Sulfamate derivative compounds for use in treating or alleviating pain SULT2A1, SULT1A1, TRPV1 ABCB1 2655/4885POLB 4621/4885PRKCA 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.